VNDA
Vanda Pharmaceuticals Inc. NASDAQ Listed Apr 12, 2006$6.38
Mkt Cap $377.1M
52w Low $3.81
41.9% of range
52w High $9.94
50d MA $7.59
200d MA $6.14
P/E (TTM)
-1.9x
EV/EBITDA
-3.2x
P/B
1.3x
Debt/Equity
0.0x
ROE
-67.4%
P/FCF
-4.7x
RSI (14)
—
ATR (14)
—
Beta
0.71
50d MA
$7.59
200d MA
$6.14
Avg Volume
2.5M
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
2200 Pennsylvania Avenue NW · Washington, DC 20037 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.69 | -0.82 | -19.2% | 7.44 | -5.8% | -14.1% | — | — | — | — | — |
| Feb 11, 2026 | AMC | -2.18 | -0.46 | +78.9% | 7.43 | -3.8% | -17.6% | -0.5% | +1.8% | -2.7% | +1.2% | — |
| Oct 29, 2025 | AMC | -0.31 | -0.38 | -22.6% | 5.41 | -7.9% | -20.1% | +0.7% | +2.8% | -2.7% | +2.1% | — |
| Jul 31, 2025 | AMC | -0.34 | -0.46 | -35.3% | 4.26 | -0.2% | -1.6% | +1.7% | -1.2% | +0.2% | -0.5% | — |
| May 7, 2025 | AMC | -0.55 | -0.50 | +9.1% | 4.38 | +1.1% | -3.7% | -6.4% | +2.0% | -1.2% | -1.5% | — |
| Feb 13, 2025 | AMC | -0.14 | -0.08 | +42.9% | 4.70 | -2.6% | -6.0% | +0.9% | +2.0% | -1.3% | -1.3% | — |
| Nov 6, 2024 | AMC | -0.17 | -0.09 | +47.1% | 4.89 | -1.8% | +2.7% | +3.4% | +2.9% | +1.1% | +1.1% | — |
| Jul 31, 2024 | AMC | -0.21 | -0.08 | +61.9% | 5.84 | +0.3% | -3.4% | -4.3% | -1.7% | +0.0% | -2.1% | — |
| May 8, 2024 | AMC | 0.05 | -0.07 | -240.0% | 5.36 | -3.9% | -6.5% | +0.6% | +0.2% | +1.6% | +4.5% | — |
| Feb 7, 2024 | AMC | -0.09 | -0.04 | +55.6% | 3.64 | +0.3% | +11.8% | +2.2% | +4.1% | -6.2% | +4.7% | — |
| Nov 8, 2023 | AMC | 0.00 | 0.00 | +100.8% | 4.33 | -3.5% | -21.9% | +0.9% | +0.0% | +4.1% | +0.0% | — |
| Jul 27, 2023 | AMC | -0.13 | 0.03 | +123.1% | 6.46 | -1.9% | -8.0% | -2.7% | -2.4% | -2.5% | +2.5% | — |
| May 3, 2023 | AMC | — | 0.06 | — | 6.39 | +0.0% | +7.5% | +1.2% | -0.3% | -1.5% | -0.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.76 | $8.05 | +39.8% | +41.5% | +0.2% | +1.3% | +3.9% | +3.6% |
| Jan 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.25 | $8.30 | +0.6% | -4.6% | +3.3% | +5.0% | -14.1% | -0.1% |
| Dec 31 | B. Riley Securities | Maintains | Buy → Buy | — | $7.03 | $8.53 | +21.3% | +25.5% | -6.5% | -4.6% | +3.3% | +5.0% |
| Dec 31 | Jefferies | Maintains | Hold → Hold | — | $7.03 | $8.53 | +21.3% | +25.5% | -6.5% | -4.6% | +3.3% | +5.0% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.35 | $5.30 | -0.9% | -3.9% | -5.8% | -0.8% | +1.9% | +2.2% |
| Oct 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.41 | $4.98 | -7.9% | -20.1% | +0.7% | +2.8% | -2.7% | +2.1% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.60 | $4.62 | +0.4% | -2.0% | +5.3% | -2.9% | +1.3% | -1.1% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.37 | $4.38 | +0.2% | +0.2% | -3.7% | -6.4% | +2.0% | -1.2% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.59 | $4.57 | -0.4% | -2.0% | +0.2% | -3.1% | -5.3% | +1.2% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.42 | $4.54 | +2.7% | +0.9% | +2.0% | -1.3% | -1.3% | -1.8% |
| Feb 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.31 | $4.31 | +0.0% | +3.9% | +1.1% | +3.5% | +2.3% | -3.8% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.45 | $4.42 | -0.7% | -0.2% | +2.0% | +1.1% | -3.7% | -2.3% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.36 | $4.40 | +0.9% | +3.4% | -3.5% | +1.6% | -0.5% | +1.1% |
| Dec 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.78 | $4.77 | -0.2% | -2.1% | +3.2% | -0.4% | +0.0% | -0.6% |
| Aug 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.84 | $5.86 | +0.3% | -3.4% | -4.3% | -1.7% | +0.0% | -2.1% |
| Feb 25 | Jefferies | Downgrade | Buy → Hold | — | $12.73 | $11.73 | -7.9% | -12.2% | +1.6% | -0.1% | -1.9% | -1.3% |
| May 12 | BofA Securities | Maintains | Buy → Buy | — | $17.83 | $18.05 | +1.2% | -0.2% | +3.4% | +1.3% | -0.4% | -1.6% |
| Jan 14 | Citigroup | Downgrade | Buy → Neutral | — | $14.00 | $13.36 | -4.6% | -0.1% | -1.8% | +1.7% | +4.1% | +0.1% |
| Oct 29 | Citigroup | Upgrade | Neutral → Buy | — | $10.09 | $11.17 | +10.8% | +9.0% | -2.7% | +2.5% | +3.8% | +6.1% |
| Jun 9 | Citigroup | Downgrade | Buy → Neutral | — | $11.64 | $11.18 | -4.0% | -4.7% | -1.6% | -3.1% | +0.9% | +4.2% |
| Mar 12 | Citigroup | Upgrade | Neutral → Buy | — | $10.60 | $10.72 | +1.1% | -2.6% | -0.8% | -20.9% | -1.2% | -6.2% |
| Feb 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $11.47 | $10.10 | -11.9% | -1.3% | -2.8% | +0.3% | +0.8% | +0.2% |
| Feb 26 | Stifel | Maintains | Hold → Hold | — | $11.47 | $10.10 | -11.9% | -1.3% | -2.8% | +0.3% | +0.8% | +0.2% |
| Aug 1 | Citi | Upgrade | Neutral → Buy | — | $12.45 | $15.50 | +24.5% | +26.8% | -3.0% | +0.1% | +1.2% | -1.0% |
| Aug 1 | Citigroup | Upgrade | Neutral → Buy | — | $12.45 | $15.50 | +24.5% | +26.8% | -3.0% | +0.1% | +1.2% | -1.0% |
| Jul 25 | Stifel | Downgrade | Buy → Hold | — | $13.19 | $12.01 | -8.9% | -7.0% | +1.5% | +0.7% | +0.8% | -1.6% |
| Jul 25 | Stifel Nicolaus | Downgrade | Buy → Hold | — | $13.19 | $12.01 | -8.9% | -7.0% | +1.5% | +0.7% | +0.8% | -1.6% |
| Feb 6 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $25.06 | $21.40 | -14.6% | -20.0% | -5.3% | -0.2% | -5.0% | +2.3% |
| Dec 11 | Oppenheimer | Downgrade | Outperform → Perform | — | $28.67 | $27.64 | -3.6% | -5.3% | -2.1% | -1.6% | +0.3% | -1.8% |
| Dec 11 | Stifel Nicolaus | Maintains | Buy → Buy | — | $28.67 | $27.64 | -3.6% | -5.3% | -2.1% | -1.6% | +0.3% | -1.8% |
| Dec 11 | Stifel | Maintains | Buy → Buy | — | $28.67 | $27.64 | -3.6% | -5.3% | -2.1% | -1.6% | +0.3% | -1.8% |
| Dec 7 | Citigroup | Maintains | Buy → Buy | — | $29.42 | $29.40 | -0.1% | -6.2% | +3.9% | -5.3% | -2.1% | -1.6% |
| Dec 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $28.94 | $29.05 | +0.4% | +1.7% | -6.2% | +3.9% | -5.3% | -2.1% |
| Dec 4 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $31.47 | $31.70 | +0.7% | -8.0% | +1.7% | -6.2% | +3.9% | -5.3% |
| Nov 8 | Jefferies | Maintains | Buy → Buy | — | $20.45 | $21.64 | +5.8% | +14.7% | +1.5% | -5.0% | -0.2% | -1.0% |
| Oct 16 | Citigroup | Maintains | Buy → Buy | — | $21.34 | $21.84 | +2.3% | +5.1% | +1.4% | -0.3% | -3.0% | -0.6% |
| Sep 21 | Oppenheimer | Maintains | Outperform → Outperform | — | $20.05 | $20.00 | -0.2% | +0.2% | +1.7% | +1.0% | +8.7% | +2.4% |
| Sep 14 | Stifel Nicolaus | Maintains | Buy → Buy | — | $18.50 | $19.00 | +2.7% | +7.6% | -4.0% | +1.8% | +1.0% | +2.0% |
| Aug 23 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $21.25 | $21.20 | -0.2% | -3.1% | +3.4% | -3.3% | -2.9% | +1.8% |
| May 23 | Citigroup | Maintains | Buy → Buy | — | $16.60 | $17.25 | +3.9% | +1.8% | +1.8% | +0.3% | +0.0% | +0.3% |
| Jan 19 | Seaport Global | Maintains | Buy → Buy | — | $14.25 | $14.45 | +1.4% | +1.8% | +4.1% | +2.6% | +1.3% | +9.2% |
| Oct 30 | Oppenheimer | Maintains | Outperform → Outperform | — | $14.70 | $15.00 | +2.0% | +8.2% | -1.3% | -1.9% | +1.0% | +3.5% |
| May 26 | H.C. Wainwright | Maintains | Buy → Buy | — | $14.05 | $14.30 | +1.8% | +0.0% | -1.8% | -0.4% | +0.4% | +0.0% |
| Apr 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.60 | $13.95 | +2.6% | +1.1% | +1.5% | -0.7% | +4.0% | -2.4% |
| Nov 9 | Aegis Capital | Maintains | Buy → Buy | — | $15.15 | $15.65 | +3.3% | +7.9% | +1.2% | +0.0% | +2.4% | +0.7% |
| Aug 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $14.17 | $14.50 | +2.3% | +8.2% | -0.5% | +3.0% | -2.2% | -0.6% |
| Aug 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $12.25 | $12.32 | +0.6% | -4.1% | +20.6% | +8.2% | -0.5% | +3.0% |
| Aug 24 | PiperJaffray | Maintains | Overweight → Overweight | — | $12.25 | $12.32 | +0.6% | -4.1% | +20.6% | +8.2% | -0.5% | +3.0% |
| Mar 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.64 | $7.68 | +0.5% | +1.8% | -2.4% | +1.4% | +1.3% | -4.0% |
| Oct 21 | Brean Capital | Maintains | Buy → Buy | — | $10.43 | $10.82 | +3.7% | +2.0% | +2.2% | -0.7% | +1.9% | +0.2% |
No insider trades available.
8-K · 2.02
!! High
Vanda Pharmaceuticals Inc. -- 8-K 2.02: Earnings Results
Vanda Pharmaceuticals reported first-quarter 2026 financial results and is hosting a conference call, allowing investors to hear management discuss operational performance and financial condition directly.
May 6
8-K
Vanda Pharmaceuticals Inc. -- 8-K Filing
Vanda Pharmaceuticals CEO will receive $260,000 in annual restricted stock unit awards beginning in 2026, vesting one year from grant date, contingent on stockholder meeting participation.
Apr 22
8-K
First Tracks Biotherapeutics, Inc. -- 8-K Filing
First Tracks Biotherapeutics has separated from AnaptysBio through a spin-off transaction, creating an independent public company with its own governance and operational structure going forward.
Apr 20
8-K
AnaptysBio, Inc. -- 8-K Filing
AnaptysBio completed a spin-off creating First Tracks Biotherapeutics, with detailed agreements governing asset transfers, liability assumptions, and ongoing relationships between the two independent entities.
Apr 20
8-K
Unknown — 8-K Filing
This metadata-only 8-K filing suggests Vanda Pharmaceuticals likely made a routine regulatory update or disclosure amendment, presenting minimal material news that probably won't significantly impact the stock price.
Apr 2
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Vanda Pharmaceuticals disclosed information under Regulation FD, suggesting management communicated material non-public information to investors, which could indicate significant corporate developments requiring immediate market disclosure.
Mar 10
8-K
Vanda Pharmaceuticals Inc. -- 8-K Filing
Vanda Pharmaceuticals gained FDA approval for BYSANTITM (ilsaperidone), a new atypical antipsychotic for bipolar I disorder and schizophrenia, expanding its product portfolio in psychiatry.
Feb 23
8-K
Vanda Pharmaceuticals Inc. -- 8-K Filing
Vanda Pharmaceuticals disclosed 2026 executive compensation details for leadership including Mihael H., indicating the company is formalizing pay structures for its top management team going forward.
Feb 19
8-K
Vanda Pharmaceuticals Inc. -- 8-K Filing
Vanda Pharmaceuticals faces uncertainties in executing its U.S. business strategy and advancing pipeline products through clinical development and regulatory approval, which could impact investor returns if execution falls short.
Feb 11
Data updated apr 27, 2026 7:56am
· Source: massive.com